Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.springerlink.com/index/pdf/10.1007/s11912-011-0154-3
Reference66 articles.
1. Liekens S, De CE, Neyts J: Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001, 61:253-270.
2. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
3. Rini BI: Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007, 13:1098-1106.
4. •Rini BI, Michaelson MD, Rosenberg JE, et al: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748. This is a phase 2 study demonstrating substantial antitumor activity with sunitinib in patients with bevacizumab-refractory metastatic RCC.
5. Valtola R, Salven P, Heikkila P, et al: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999, 154:1381-1390.
Cited by 113 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer;Expert Opinion on Drug Metabolism & Toxicology;2024-03-20
2. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review;Frontiers in Pharmacology;2024-02-01
3. Treatments for diabetic retinopathy and diabetic macular edema in pipeline;Therapeutic Targets for Diabetic Retinopathy;2024
4. Voltage-gated sodium channel activity mediates sea urchin larval skeletal patterning through spatial regulation of Wnt5 expression;Development;2023-05-15
5. Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor;Cancer Chemotherapy and Pharmacology;2023-05-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3